USPTO grants two additional patents to Ryogen

Ryogen LLC, a genomic research and development company focusing on genes with applications in biomedical research, has been awarded two additional patents on human genes.

“We plan to continue licensing our intellectual property to make it accessible to the research community”

U.S. Patent No. 7,754,424, titled "Isolated genomic polynucleotide fragments from chromosome 12 that encode human carboxypeptidase M and the human mouse double minute 2 homolog," claims isolated genomic polynucleotide fragments that encode human mouse double minute 2 homolog as well as fragments of contiguous exon-intron and intron-exon regions, transcription factor binding regions and other noncoding regions such as 5' and 3' noncoding regions and intron regions, complementary polynucleotides, microarrays, vectors and host cells containing these fragments. The patent also claims methods for detecting the claimed polynucleotide fragments and methods for obtaining human mouse double minute 2 homolog. The protein encoded by the claimed sequences is thought to play a role in modulating production of p53 levels in an individual as well as specifically a role in treatment of sarcoma and leukemia.

U.S. Patent No. 7,786,280, titled "Isolated genomic polynucleotide fragments from chromosome 10q25.3 that encode human soluble aminopeptidase P," claims isolated genomic polynucleotide fragments that encode soluble human Aminopeptidase P, complementary polynucleotides, vectors and host cells containing these fragments and a method for obtaining soluble Aminopeptidase P. The protein encoded by the claimed sequences is thought to play a role in modulating bradykinin and substance P levels in an individual as well as specifically a role in acquired or inherited angioedema or acute pancreatitis.

"I am very pleased with the USPTO's decision to award us these patents, bringing number of our issued patents to seven," said Dr. James W. Ryan, the named inventor on the patents and Chief Scientist at Ryogen.

"These patents are important additions to the Ryogen's existing patent portfolio," said Valeria Poltorak, Ryogen's Executive Vice President. "We plan to continue licensing our intellectual property to make it accessible to the research community," she concluded.